Evidence map›Paper›PMID 19054549›Full record

SynthesisGynecologic oncology2009

Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science.

Nicolas Wentzensen, Mark E Sherman, Mark Schiffman, Sophia S Wang

Open access · greenAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Gynecologic oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
133citing papers in PubMed, 5 pooled it
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

133 citing papers in PubMed, 5 syntheses or guidelines pooled it, 262 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Clinical Regression of High-Grade Cervical Intraepithelial Neoplasia Is Associated With Absence ofJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Article
  20. Article

73 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 5012, Rockville, MD 20854-7234, USA. wentzenn@mail.nih.gov
Mark E Sherman
Mark Schiffman
Sophia S Wang
National Cancer Institute · USDivision of Cancer Epidemiology and Genetics

Funding

Human papillomavirus (HPV) infection and cervical and anal cancersZIACP010124 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI WENTZENSEN, NICOLAS · 2009 to 2025
$17.3M
CERVICAL CANCER AND HUMAN PAPILLOMAVIRUS (HPV) INFECTIONZ01CP010124 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SCHIFFMAN, MARK · 1996 to 2008
$3.0M
Intramural NIH HHS Z01 CP010124
6 · The paper itself

Abstract

objectiveWe wanted to identify the most promising methylation marker candidates for cervical cancer early detection.

methodsA systematic literature review was performed in Medline and weighted average frequencies for methylated genes stratified by tissue source and methods used were computed.

results51 studies were identified analyzing 68 different genes for methylation in 4376 specimens across all stages of cervical carcinogenesis. 15 genes, DAPK1, RASSF1, CDH1, CDKN2A, MGMT, RARB, APC, FHIT, MLH1, TIMP3, GSTP1, CADM1, CDH13, HIC1, and TERT have been analyzed in 5 or more studies. The published data on these genes is highly heterogeneous; 7 genes (CDH1, FHIT, TERT, CDH13, MGMT, TIMP3, and HIC1) had a reported range of methylation frequencies in cervical cancers of greater than 60% between studies. Stratification by analysis method did not resolve the heterogeneity. Three markers, DAPK1, CADM1, and RARB, showed elevated methylation in cervical cancers consistently across studies.

conclusionsThere is currently no methylation marker that can be readily translated for use in cervical cancer screening or triage settings. Large, well-conducted methylation profiling studies of cervical carcinogenesis could yield new candidates that are more specific for HPV-related carcinogenesis. New candidate markers need to be thoroughly validated in highly standardized assays.

Indexed as

DNA MethylationAdenocarcinomaCarcinoma, Squamous CellEarly Detection of CancerFemaleGenetic MarkersHumansPapillomavirus InfectionsUterine Cervical DysplasiaUterine Cervical NeoplasmsGenetic Markers

Identifiers

PMID19054549
PMCPMC2673716
OpenAlexW1963744267

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.